Company Overview and News

2
Lexaria Bioscience: DehydraTECH Could Transform Oral Delivery In Cannabis, Nicotine, NSAIDs, And Vitamins

1h seekingalpha
Lexaria Bioscience is a growing company whose DehydraTECH could be revolutionary in improving the delivery of active pharmaceutical ingredients.
LXX NU LXRP

2
Lexaria Bioscience Receives Two New Granted Patents

1h accesswire
KELOWNA, BC / ACCESSWIRE / October 18, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has been granted two new US patents.
LXX LXRP

41
30 Marijuana Stocks to Buy as the Future Turns Green

2018-10-17 investorplace - 3
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF

2
Lexaria Files New Patent Application for Delivery of Tobacco-Derived Products

2018-09-28 accesswire
KELOWNA, BC / ACCESSWIRE / September 28, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the filing of a new strategic patent application.
LXX LXRP

2
UPDATE: OTC Markets Group Announces Agenda for OTCQX Virtual Investor Conference on October 4

2018-09-26 accesswire
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its upcoming OTCQX® Virtual Investor Conference, on October 4, 2018, featuring US-based issuers traded on the OTCQX Best Market.
GRWG MNTR SMDM BMBMD ISDR REPR MACE DYAI ZDPY LXX OTCM FRHC TOMZ LXRP

2
OTC Markets Group Announces Agenda for OTCQX Virtual Investor Conference on October 4

2018-09-25 accesswire
NEW YORK, NY / ACCESSWIRE / September 25, 2018 / OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its upcoming OTCQX® Virtual Investor Conference, on October 4, 2018, featuring US-based issuers traded on the OTCQX Best Market.
GRWG NIOBF MNTR SMDM BMBMD ISDR REPR MACE DYAI ZDPY LXX OTCM FRHC TOMZ NB LXRP

55
30 Marijuana Stocks to Buy as the Future Turns Green

2018-09-23 investorplace - 17
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF

11
The Best 'Pick And Shovel' Plays Of Cannabis (Part II)

2018-09-21 seekingalpha - 1
In this article, we will discuss three more companies that all focus on the technologies that can be used in the cannabis industry.
LXX EVIO RTI BSTI RDDTF TLRY LXRP SMG

2
Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance

2018-09-07 accesswire
KELOWNA, BC / ACCESSWIRE / September 7, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company"or "Lexaria"), a drug delivery platform innovator, announces strategic additions to its patent portfolio.
LXX LXRP

2
Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results

2018-08-30 accesswire
KELOWNA, BC / ACCESSWIRE / August 30, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CNSX: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces further results from its recently completed second-generation study in 40 rats (two groups of 20 each) in addition to those released on August 7, 2018.
LXX LXRP

2
Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing: Delivery Measured Within Minutes

2018-08-07 accesswire
KELOWNA, BC / ACCESSWIRE /August 7, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP; CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that it has successfully delivered nicotine in an edible form into blood plasma just minutes after dosing in an animal in vivo study. Lexaria's DehydraTECH™ technology delivered nicotine at each of the 2, 4, 6, 8 and 10-minute intervals post-dosing, with 90.
LXX LXRP

2
Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

2018-08-01 accesswire
KELOWNA, BC / ACCESSWIRE / August 1, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to report significant bioavailability results from its randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD TM - a proprietary, DehydraTECH™ powered, cannabidiol ("CBD") fortified hemp oil capsule developed by Lexaria.
LXX GWP LXRP

2
Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

2018-07-31 accesswire
KELOWNA, BC and TORONTO, ON / ACCESSWIRE / July 31, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX); the "Company" or "Lexaria"), a drug delivery platform innovator, and Hill Street Beverage Company Inc., (BEER; "Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval.
LXX LXRP

92
The BAK Portfolio: Canadian Weed Is Legal And The Green Rush Has Begun

2018-07-17 seekingalpha
An escalating trade war and a tepid rebound in Canadian cannabis stocks left the portfolio running in the red for the second quarter in a row.
LXX TAP GRWG TWMJF KHRNF MICWF WEED RTI APHQF CGC LXRP

2
Lexaria Announces 2018 AGM Results and Corporate Update

2018-07-03 accesswire
KELOWNA, BC / ACCESSWIRE / July 3, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special Meeting. All motions were passed.
LXX LXRP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:LXX / Lexaria Bioscience Corp. on message board site Silicon Investor.

LEXON INC. (LXXN:BB) LEXON INC. (LXXN:BB) LEXON INC. (LXXN:BB) LXXI LXXI LXXI
CLXX(CELLEX BIOSCIENCES) CLXX(CELLEX BIOSCIENCES) CLXX(CELLEX BIOSCIENCES)